Plasmodium Falciparum Malaria Clinical Trial
Official title:
Malaria Transmission and Immunity in Highland Kenya
NCT number | NCT00393757 |
Other study ID # | 05-0124 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2006 |
Est. completion date | January 31, 2011 |
Verified date | October 2007 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to see why malaria epidemics occur in highland areas in Kenya. A better understanding of factors contributing to malaria may be necessary for malaria vaccine planning. These factors include interactions between age, where malaria is passed from mosquitoes to people, immune system (how the body fights infection) responses and other factors that contribute to malaria in epidemic-prone areas. About 6400 people from the villages of Kapsisiywa and Kipsamoite will participate. Study procedures will include in home surveys, which will involve a census and an interview by researchers. Blood samples and smears will be collected from some volunteers in both communities to understand how the body protects itself from malaria and to check for malaria parasites. Twice each month, random houses will be selected from 3 places in the village to measure the number of mosquitoes in the home. Participants may be involved in the study for up to 4 years.
Status | Completed |
Enrollment | 20610 |
Est. completion date | January 31, 2011 |
Est. primary completion date | January 31, 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 99 Years |
Eligibility |
Inclusion Criteria: Active surveillance of clinical malaria -Individuals of any age who live in the area (Kipsamoite or Kapsisiywa) for more than 6 months of the year, or, if they are new to the area, who plan to live in the area for more than 6 months of the year (permanent residents). Passive surveillance of clinical malaria -Any individual living within the boundaries of the 2 study areas (Kipsamoite and Kapsisiywa) Exclusion Criteria: Active surveillance of clinical malaria - Declining to participate in the study - Will be gone from site more than 1 week per month - Not available for weekly symptom check or bimonthly blood sample collection Passive surveillance of clinical malaria - Declining to participate in the study - Participation in active surveillance study |
Country | Name | City | State |
---|---|---|---|
Kenya | Kenya Medical Research Institute | Kisumu |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
Kenya,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04577066 -
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
|
Phase 1/Phase 2 | |
Completed |
NCT01883609 -
A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S
|
Phase 1/Phase 2 | |
Completed |
NCT00593398 -
Malarial Immunity in Pregnant Cameroonian Women
|
||
Completed |
NCT01659281 -
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
|
N/A | |
Completed |
NCT00074841 -
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
|
Phase 2/Phase 3 | |
Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
Completed |
NCT00314899 -
Fetal Immunity to Falciparum Malaria
|
||
Completed |
NCT02867059 -
SJ733 Induced Blood Stage Malaria Challenge Study
|
Phase 1 | |
Completed |
NCT00701961 -
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
|
Phase 2/Phase 3 | |
Completed |
NCT00707200 -
The Cytoadherence in Pediatric Malaria (CPM) Study
|
N/A | |
Completed |
NCT00338520 -
Hyperphenylalaninemia in Cerebral Malaria
|
N/A | |
Completed |
NCT03783299 -
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
|
Phase 4 | |
Completed |
NCT02614404 -
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 1 | |
Completed |
NCT00358332 -
Phase I Pediatric FMP2.1/AS02A Trial in Mali
|
Phase 1 | |
Completed |
NCT00730782 -
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
|
Phase 1 | |
Completed |
NCT00349713 -
FMP2.1 Trial in Bandiagara, Mali
|
Phase 1 | |
Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
Completed |
NCT04093765 -
Mass Screening and Treatment for Reduction of Falciparum Malaria
|
N/A | |
Completed |
NCT03764527 -
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
|
Phase 4 | |
Completed |
NCT03773536 -
Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar
|
Phase 4 |